RT Journal Article
T1 [Perception of physicians on factors that influence the choice of a dicoumarin or a new oral anticoagulant in patients with non-valvular atrial fibrillation].
T2 Percepción de los médicos sobre los factores que influyen en la elección de un dicumarínico o de un nuevo anticoagulante oral en pacientes con fibrilación auricular no valvular.
A1 Anguita-Sánchez, Manuel
A1 Marco-Vera, Pascual
A1 Alonso-Moreno, Francisco J
A1 Arribas-Ynsaurriaga, Fernando
A1 Gállego-Culleré, Jaime
A1 Honorato-Pérez, Jesús
A1 Suárez-Fernández, Carmen
A1 Investigadores del estudio ACADEMIC, 
K1 Anticoagulantes orales
K1 Anticoagulants
K1 Atrial fibrillation
K1 Embolia
K1 Embolisms
K1 Fibrilación auricular
AB Recent studies have demonstrated the efficacy and safety of new oral anticoagulant drugs for the prevention of thromboembolic events in patients with non-valvular atrial fibrillation. Our aim was to evaluate the factors that can influence physicians in their choice between a classic and a new anticoagulant in these patients. Several variables of interest were discussed and analysed using a WorkmatTM methodology. Six regional meetings were held in Spain (East, Catalonia, Andalusia-Extremadura, Madrid, North-east, and North of Spain). Meetings were attended by 39 specialists (cardiologists, neurologists, haematologists, internists, and emergency and Primary Care physicians). Each participant graded their level of agreement, with a score from 1 to 10, on every analysed variable. A new anticoagulant drug was preferred in patients with previous failure of dicoumarin therapy (9.7±0.5), high haemorrhagic risk (8.7±1), prior bleeding (7.8±1.5), and high thrombotic risk (7.7±1.2). Dicoumarins were preferred in cases of severe (1.2±0.4) or moderate (4.2±2.5) kidney failure, good control with dicoumarins (2.3±1.5), cognitive impairment (3.2±3), and low haemorrhagic risk (4.3±3). Age, sex, weight, cost of drug, polymedication, and low thrombotic risk achieved intermediate scores. There were no differences between the different specialists or Spanish regions. The presence of a high thrombotic or haemorrhagic risk and the failure of previous dicoumarin therapy lead to choosing a new oral anticoagulant in patients with non-valvular atrial fibrillation, while kidney failure, cognitive impairment, good control with dicoumarins, and a low bleeding risk predispose to selecting a classic dicoumarin anticoagulant.
YR 2016
FD 2016-03-10
LK http://hdl.handle.net/10668/9914
UL http://hdl.handle.net/10668/9914
LA es
DS RISalud
RD Apr 8, 2025